In indirect comparisons, finerenone was associated with lower risk of worsening HF events versus canagliflozin (OR = 2.12, 95% CI 1.13-3.98) and RASi (OR = 1.21, 95% CI 1.03-1.42). Here, MMP19 is linked to hydrops fetalis.